Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Allero Therapeutics from Gent, company number BE0665757817, closed financial year 2025 with a result of € -3,030 after tax. For that financial year Allero Therapeutics recorded a gross margin of € -2,308 and equity of € 68,509. Compared with financial year 2024, the result moved from € 123 to € -3,030. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ 68,509
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3,030
▼ still € 123 profit in 2024
Profit after tax over the fiscal year.
€ 981
▼ 61% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -25,041.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,375
▲ 39% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 249,450 | € -15,040 | € -2,286 | € -2,308 | ▼ € 23 |
| Profit after taxes | € 254,322 | € -11,756 | € 123 | € -3,030 | ▼ € 3,152 |
| Equity | € 83,172 | € 71,416 | € 71,539 | € 68,509 | ▼ 4% |
| Total debts | € 320,484 | € 9,514 | € 8,636 | € 10,015 | ▲ 16% |
| Cash | € 8,257 | € 6,276 | € 2,520 | € 981 | ▼ 61% |
| Retained profit | € -10,378 | € -22,134 | € -22,011 | € -25,041 | ▼ € 3,030 |
| Balance sheet total | € 403,655 | € 80,930 | € 80,174 | € 78,524 | ▼ 2% |
Key figures of Allero Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Allero Therapeutics?
What happened at Allero Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3,030 (▼ € 3,152 vs 2024). Source: NBB ↗
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
- Emil POT became a director. NBB
In short
From € 254,322 profit in 2022 to € 3,030 loss in 2025.
Best year ever: 2022, with € 254,322 profit.
Management
The stake of SAEM-4U comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Allero TherapeuticsBehind Allero Therapeutics is Emil POT. The shares are held by SAEM-4U (100%). It owns 51.4% of Allero Therapeutics itself.
Directors
According to the 2025 annual accounts
since 2016
Shareholders
100%
Participations
Allero Therapeutics
51.4%
Establishments
Establishment units
Physical locations of this company
Onderstraat 7 box 211
9000 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0665.757.817
- VAT number
- BE 0665.757.817
- Registered office
- Onderstraat 7 bus 211, 9000 Gent
- Names & denominations
- Allero Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 November 2016
- Peppol
- Active · Active since 6 Nov 2025